Important priorities for control and eventual elimination of TB include rapid identification and treatment of individuals with active TB and laboratory diagnosis and treatment of individuals with latent TB infection (LTBI). LTBI screening should be considered for healthcare workers, those newly arriving in Ireland and individuals commencing immunosuppressive therapy.
Currently, two types of tests for the diagnosis of latent TB infections are used: tuberculin skin tests (TSTs) and Interferon-γ release assays (IGRAs). The QuantiFERON-TB Gold is one such IGRA assay which is intended for use in conjunction with risk assessment, radiography, and other medical and diagnostic evaluation.